Gisbert, Javier P. http://orcid.org/0000-0003-2090-3445
Chaparro, María
Funding for this research was provided by:
Universidad Autónoma de Madrid
Article History
Accepted: 21 June 2023
First Online: 28 July 2023
Declarations
:
: JP Gisbert wrote the first draft of the manuscript and critically reviewed the final version. M Chaparro complemented draft sections and critically reviewed the final version.
: Dr Gisbert has served as speaker, consultant, and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Kern Pharma, Biogen, Mylan, Takeda, Janssen, Roche, Sandoz, Celgene/Bristol Myers, Gilead/Galapagos, Lilly, Ferring, Faes Farma, Shire Pharmaceuticals, Dr Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, Norgine and Vifor Pharma. Dr Chaparro has served as a speaker, or has received research or education funding from MSD, Abbvie, Hospira, Pfizer, Takeda, Janssen, Ferring, Shire Pharmaceuticals, Dr Falk Pharma, Tillotts Pharma, Lilly.
: Not applicable.
: Not applicable.
: All authors give their consent to publish this article.
: Not applicable.
: No new data are generated.
: Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature.